Q-omics provides the consensus-scored PLEKHJ1 profile across patient tissues and cancer cell-line models. PLEKHJ1 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, PLEKHJ1 is differentially expressed in 13, with the highest sampling consensus in BLCA. Additionally, PLEKHJ1 protein abundance shows 24,669 significant protein co-abundance associations, with the highest sampling consensus in HNSC. Together, these results highlight ACC, BLCA, and HNSC as cancer lineages where PLEKHJ1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for PLEKHJ1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes PLEKHJ1 survival associations across molecular data types. PLEKHJ1 RNA expression shows survival associations in the most cancer types (24), followed by mass-spec protein abundance (11). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible PLEKHJ1 RNA expression–survival associations across cancer types. High PLEKHJ1 expression shows unfavorable associations in ACC, LIHC, LAML, PRAD and BRCA, but favorable associations in STAD. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for PLEKHJ1 RNA expression.
This table summarizes PLEKHJ1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13, while mass-spec protein shows differences in 10. The strongest signals are observed in BLCA for RNA and HNSC for protein.
This table ranks reproducible tumor–normal expression differences for PLEKHJ1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. PLEKHJ1 shows lower tumor expression in THCA and KIRC and higher tumor expression in BLCA, LIHC, KICH and UCEC. The BLCA box plot shows higher PLEKHJ1 RNA expression in tumor versus normal tissue (log2 FC = +1.175, t-test p < 0.001).
This table shows molecular features associated with PLEKHJ1 in patient tissues and cancer cell lines. In patient samples, PLEKHJ1 shows the broadest associations at the RNA and protein expression levels, with HNSC recurring as the lineage with the largest associated feature set. In cancer cell lines, PLEKHJ1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SOFT_TISSUE, while CRISPR and shRNA rows add functional-dependency signals in SKIN and UPPER_AERODIGESTIVE_TRACT.
